CO6300939A2 - Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada - Google Patents

Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada

Info

Publication number
CO6300939A2
CO6300939A2 CO10116702A CO10116702A CO6300939A2 CO 6300939 A2 CO6300939 A2 CO 6300939A2 CO 10116702 A CO10116702 A CO 10116702A CO 10116702 A CO10116702 A CO 10116702A CO 6300939 A2 CO6300939 A2 CO 6300939A2
Authority
CO
Colombia
Prior art keywords
referring
related application
new compounds
erk inhibitors
formula
Prior art date
Application number
CO10116702A
Other languages
English (en)
Spanish (es)
Inventor
Alan B Cooper
Yang Nan
Xin Yao
Liang Zhu
Xiaolei Gao
Abdul-Basit Alhassan
Sobhana Babu Boga
Hon-Chung Tsui
Sunil Paliwal
James J-S Wang
Jagdish Desai
Mehul Patel
Ronald J Doll
Subrahmanyam Gudipati
Joseph M Kelly
Hugh Y Zhu
Neng-Yang Shih
Gerald W Shipps Jr
Yongqi Deng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300939(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO6300939A2 publication Critical patent/CO6300939A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO10116702A 2008-02-21 2010-09-21 Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada CO6300939A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
CO6300939A2 true CO6300939A2 (es) 2011-07-21

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10116702A CO6300939A2 (es) 2008-02-21 2010-09-21 Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada

Country Status (23)

Country Link
US (1) US8716483B2 (forum.php)
EP (1) EP2260031B1 (forum.php)
JP (1) JP5276676B2 (forum.php)
KR (1) KR20100117123A (forum.php)
CN (1) CN102015693B (forum.php)
AR (1) AR070460A1 (forum.php)
AU (1) AU2009215534B8 (forum.php)
BR (1) BRPI0908120A8 (forum.php)
CA (1) CA2714479A1 (forum.php)
CL (1) CL2009000394A1 (forum.php)
CO (1) CO6300939A2 (forum.php)
EC (1) ECSP10010415A (forum.php)
ES (1) ES2556353T3 (forum.php)
IL (1) IL207530A (forum.php)
MX (1) MX2010009268A (forum.php)
MY (1) MY152271A (forum.php)
NZ (1) NZ587504A (forum.php)
PE (1) PE20091491A1 (forum.php)
RU (1) RU2525389C2 (forum.php)
SG (1) SG188179A1 (forum.php)
TW (1) TWI398441B (forum.php)
WO (1) WO2009105500A1 (forum.php)
ZA (2) ZA201005909B (forum.php)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EP1984331B1 (en) 2006-02-16 2010-10-20 Schering Corporation Pyrrolidine derivatives as erk inhibitors
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
EP2483263B1 (en) 2009-09-30 2018-07-18 Merck Sharp & Dohme Corp. Heterocyclic compounds that are erk inhibitors
US8999957B2 (en) * 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9173396B2 (en) 2010-10-22 2015-11-03 Bayer Intellectual Property Gmbh Heterocyclic compounds as pesticides
CA2818561A1 (en) * 2010-11-16 2012-05-24 Medimmune, Llc Regimens for treatments using anti-igf antibodies
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
AU2013225737B2 (en) 2012-03-01 2018-03-01 Array Biopharma Inc. Serine/threonine kinase inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2875001B1 (en) * 2012-07-18 2019-01-09 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
WO2014052563A2 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2900223B1 (en) * 2012-09-28 2017-10-25 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2970329A1 (en) * 2013-03-13 2016-01-20 F. Hoffmann-La Roche AG Process for making benzoxazepin compounds
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
ME02991B (me) 2013-10-03 2018-10-20 Kura Oncology Inc Ekr inhibitori i postupci primene
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
CA2970717A1 (en) 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MX2017008078A (es) * 2014-12-19 2017-09-28 Merck Sharp & Dohme Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
SI3277690T1 (sl) * 2015-04-03 2020-07-31 Recurium Ip Holdings, Llc Spirociklične spojine
WO2017040362A1 (en) * 2015-09-03 2017-03-09 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
CN114761411B (zh) 2019-12-06 2023-05-12 南京明德新药研发有限公司 作为erk抑制剂的螺环类化合物及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
SK14082001A3 (sk) 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
MXPA03002291A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
IL154710A0 (en) 2000-09-15 2003-10-31 Vertex Pharma Isoxazole derivatives and pharmaceutical compositions containing the same
WO2002046158A2 (en) 2000-11-20 2002-06-13 Scios Inc. Piperidine/piperazine-type inhibitors of p38 kinase
ATE340172T1 (de) 2000-12-21 2006-10-15 Vertex Pharma Pyrazolverbindungen als protein- kinasehemmer
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
ATE449763T1 (de) * 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
EP1461334A2 (en) 2001-04-27 2004-09-29 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
JP4342939B2 (ja) 2001-08-03 2009-10-14 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターおよびその使用
US6750239B2 (en) 2001-08-03 2004-06-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
US7253199B2 (en) 2001-10-23 2007-08-07 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003233605A1 (en) 2002-05-24 2003-12-12 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
JP4414881B2 (ja) * 2002-05-31 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾール化合物およびこれを含んでなる医薬組成物
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003295332B2 (en) 2002-09-19 2007-01-18 Merck Sharp & Dohme Corp. Imidazopyridines as cyclin dependent kinase inhibitors
US7456190B2 (en) 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
AU2004293035A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Methods of treating diseases and disorders by targeting multiple kinases
EP1715871A1 (en) 2003-12-22 2006-11-02 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
JP2007530595A (ja) 2004-03-26 2007-11-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋ２のピリジンインヒビターおよびそれらの使用
WO2005100338A1 (en) 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
MXPA06013208A (es) 2004-05-14 2007-01-16 Vertex Pharma Profarmacos de pirrolipirimidina como inhibidotes de la proteina cinasa erk.
EP3305776B1 (en) 2004-05-14 2019-09-25 Vertex Pharmaceuticals Incorporated Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
JP2008525461A (ja) 2004-12-23 2008-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋプロテインキナーゼの選択的阻害剤およびその使用
CN100377868C (zh) * 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
MY149430A (en) * 2005-12-13 2013-08-30 Merck Sharp & Dohme Polycyclic indazole derivatives that are erk inhibitors
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EP1984331B1 (en) 2006-02-16 2010-10-20 Schering Corporation Pyrrolidine derivatives as erk inhibitors
JPWO2007123186A1 (ja) * 2006-04-20 2009-09-03 武田薬品工業株式会社 医薬
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
WO2008005268A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US7671832B2 (en) * 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Inhibitors of brutons tyrosine kinase
MY148609A (en) * 2007-06-05 2013-05-15 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
AU2008262038A1 (en) 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
MX2009014208A (es) 2007-06-18 2010-01-28 Schering Corp Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
EP2483263B1 (en) 2009-09-30 2018-07-18 Merck Sharp & Dohme Corp. Heterocyclic compounds that are erk inhibitors

Also Published As

Publication number Publication date
NZ587504A (en) 2012-09-28
EP2260031A1 (en) 2010-12-15
RU2010138635A (ru) 2012-03-27
EP2260031B1 (en) 2015-10-07
AU2009215534B8 (en) 2014-07-10
ZA201005909B (en) 2014-03-26
AU2009215534A1 (en) 2009-08-27
TW200948799A (en) 2009-12-01
ES2556353T3 (es) 2016-01-15
AR070460A1 (es) 2010-04-07
AU2009215534A2 (en) 2010-12-23
JP5276676B2 (ja) 2013-08-28
CL2009000394A1 (es) 2011-02-11
WO2009105500A1 (en) 2009-08-27
US20110189192A1 (en) 2011-08-04
CN102015693A (zh) 2011-04-13
IL207530A (en) 2014-08-31
AU2009215534B2 (en) 2014-06-26
BRPI0908120A2 (forum.php) 2017-08-22
RU2525389C2 (ru) 2014-08-10
US8716483B2 (en) 2014-05-06
AU2009215534A8 (en) 2014-07-10
BRPI0908120A8 (pt) 2017-10-24
CN102015693B (zh) 2014-10-29
CA2714479A1 (en) 2009-08-27
KR20100117123A (ko) 2010-11-02
IL207530A0 (en) 2010-12-30
ZA201400396B (en) 2014-12-23
MX2010009268A (es) 2010-09-14
MY152271A (en) 2014-09-15
PE20091491A1 (es) 2009-09-25
ES2556353T8 (es) 2017-10-13
TWI398441B (zh) 2013-06-11
SG188179A1 (en) 2013-03-28
JP2011513225A (ja) 2011-04-28
ECSP10010415A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR20120414A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
CR20150045A (es) Inhibidores de hepatitis c
UY32049A (es) Inhibidores de cmet
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
UY30001A1 (es) Alquilsulfonamida quinolinas
DOP2011000053A (es) Agentes antifungicos
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso

Legal Events

Date Code Title Description
FC Application refused
FG Application granted